Alpha-1 MP
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Emphysema in Alpha-1 PI Deficiency
Conditions
Pulmonary Emphysema in Alpha-1 PI Deficiency
Trial Timeline
Nov 1, 2013 → Jan 1, 2027
NCT ID
NCT01983241About Alpha-1 MP
Alpha-1 MP is a phase 3 stage product being developed by Grifols for Pulmonary Emphysema in Alpha-1 PI Deficiency. The current trial status is active. This product is registered under clinical trial identifier NCT01983241. Target conditions include Pulmonary Emphysema in Alpha-1 PI Deficiency.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Emphysema in Alpha-1 PI Deficiency were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02870348 | Phase 1/2 | Completed |
| NCT02870309 | Phase 1/2 | Completed |
| NCT02796937 | Phase 3 | Recruiting |
| NCT01983241 | Phase 3 | Active |
Competing Products
20 competing products in Pulmonary Emphysema in Alpha-1 PI Deficiency